Ricevi le ultime notizie sulle azioni Rani Therapeutics Hldgs con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di RANI

Ultime notizie per

RANI THERAPEUTICS HOLDINGS-A

Rani Therapeutics Hldgs

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Holdings Inc

News

Press Releases

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Health Care

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Earnings

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Research Agreement with Chugai

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Power Metallic (TSXV: PNPN | OTCQB: PNPNF) Closes Strategic Acquisition, Expanding Nisk Footprint – More Stocks Inside

Financing

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Penny Stocks

Small Cap

Biotech Stocks Positioned to Transform Treatment With Next-Gen Therapeutics

CLIK

LIFFF

MDCX

PNPNF

PRTC

RANI

SDST

SNYR

TSXV:LIFT

TSXV:PNPN

WINT

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Aytu BioPharma

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Curanex Pharmaceuticals Inc - Common Stock

Curanex Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

Hoth Therapeutics

IGC Pharma

Iterum Therapeutics

Incannex Healthcare

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

ProPhase Labs

Pulmatrix

PolyPid

SCYNEXIS

SenesTech

Traws Pharma

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Oppenheimer

HC Wainwright & Co.

Canaccord Genuity

Maxim Group

Comments

Rani Therapeutics Hldgs Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO